SOPHiA GENETICS SA (SOPH)
NASDAQ: SOPH · Real-Time Price · USD
7.14
+0.52 (7.85%)
At close: Nov 6, 2026, 4:00 PM EST
7.28
+0.14 (1.96%)
After-hours: Nov 6, 2026, 7:38 PM EST
SOPHiA GENETICS Revenue
SOPHiA GENETICS had revenue of $24.27M in the quarter ending September 30, 2026, with 24.69% growth. This brings the company's total for the last twelve months to $90.97M, up 24.11% year-over-year. In the year 2025, SOPHiA GENETICS had annual revenue of $77.27M with 18.56% growth. That makes SOPHiA GENETICS the 23,402nd largest company in the world by revenue and 3,358th in the United States.
Revenue (ttm)
$90.97M
Revenue Growth
+24.11%
P/S Ratio
6.72
Revenue / Employee
$219,210
Employees
415
Market Cap
611.60M
Revenue by Geography
- Rest of Europe, The Middle East, and Africa (EMEA) 25.65M 33.2%
- France 11.32M 14.6%
- United States 10.87M 14.1%
- Italy 10.81M 14.0%
- Spain 6.03M 7.8%
- Asia-Pacific (APAC) 5.21M 6.7%
- Latin America (LATAM) 3.09M 4.0%
- Other 4.30M 5.6%
Fiscal year ended Dec 31, 2025 See the full SOPHiA GENETICS breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 77.27M | 12.10M | 18.56% |
| Dec 31, 2024 | 65.17M | 2.80M | 4.49% |
| Dec 31, 2023 | 62.37M | 14.81M | 31.14% |
| Dec 31, 2022 | 47.56M | 7.11M | 17.58% |
| Dec 31, 2021 | 40.45M | 12.05M | 42.43% |
| Dec 31, 2020 | 28.40M | 3.04M | 11.98% |
| Dec 31, 2019 | 25.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Teladoc Health | 2.47B |
| Evolent Health | 2.34B |
| Omnicell | 1.24B |
| Claritev | 994.67M |
| GoodRx Holdings | 785.23M |
| Phreesia | 507.79M |
| Omada Health | 333.04M |
| HealthStream | 327.95M |
SOPH News
- 5 days ago - SOPHiA GENETICS Earnings Call Transcript: Q3 2026 - Transcripts
- 5 days ago - SOPHiA GENETICS Slides: Q3 2026 - Filings
- 5 days ago - SOPHiA GENETICS Earnings release: Q3 2026 - Filings
- 5 days ago - Sophia Genetics reports Q3 EPS (24c), consensus (20c) - TheFly
- 5 days ago - Sophia Genetics backs FY26 revenue view $94M-$96M, consensus $95.23M - TheFly
- 5 days ago - SOPHiA GENETICS Reports Third Quarter 2026 Results - PRNewsWire
- 19 days ago - SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026 - PRNewsWire
- 4 weeks ago - Myriad, Sophia advance prostate cancer-specific genomic instability score tech - TheFly